← Latest news 
Dr Reddy’s bets on semaglutide and abatacept to revive margins and momentum by FY27
Business
Published on 14 May 2026
US pressure eased but margins hinge on new launches
Dr Reddy’s Laboratories expects a gradual recovery in the coming fiscal year after last year’s profit dip hit by pressures in the US business. Growth remains solid across India, Europe, and emerging markets. The company’s outlook leans on upcoming launches including semaglutide and abatacept, alongside improved product mix and tighter cost controls to lift margins by FY27.
- Profit fell last year amid US business pressures
- India, Europe and emerging markets are growing steadily
- Semaglutide and abatacept launches could fuel future expansion
- Margin recovery depends on better mix and cost controls
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times